Amebic meningoencephalitides and keratitis: Challenges in diagnosis and treatment

Current Opinion in Infectious Diseases

Volumn 23, Issue 6, 2010, Pages 590-594

  Visvesvara, Govinda S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Acanthamoeba keratitis; Acanthamoeba spp.; Balamuthia mandrillaris; granulomatous amebic encephalitis; Naegleria fowleri; primary amebic meningoencephalitis

Indexed keywords

AMPHOTERICIN B; AZITHROMYCIN; BIGUANIDE; CHLORHEXIDINE; CHLORPROMAZINE; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DIAMIDINE DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; HEXAMIDINE; HEXAMIDINE ISETIONATE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MILTEFOSINE; NEOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; POLY(HEXAMETHYLENEBIGUANIDE); PROPAMIDINE; PROPAMIDINE ISETHIONATE; RIFAMPICIN; ROKITAMYCIN; SULFADIAZINE; VORICONAZOLE;

ACANTHAMOEBA; ACANTHAMOEBA KERATITIS; ANTIPROTOZOAL ACTIVITY; BALAMUTHIA INFECTION; BALAMUTHIA MANDRILLARIS; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; DRUG EFFICACY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; GRANULOMATOUS AMEBIC ENCEPHALITIS; HUMAN; NAEGLERIA FOWLERI; NONHUMAN; PRIMARY AMEBIC MENINGOENCEPHALITIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TROPHOZOITE;

ACANTHAMOEBA; ACANTHAMOEBA KERATITIS; AMOEBIDA; ANIMALS; ANTI-INFECTIVE AGENTS; CHILD; DRUG DELIVERY SYSTEMS; HUMANS; MENINGOENCEPHALITIS; NAEGLERIA FOWLERI; YOUNG ADULT;

EID: 78349308119     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833ed78b     Document Type: Review

References (41)

1. Visvesvara GS, Moura H, Schuster FL Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Microbiol 2007; 50:1-26.
2. Khan NA. Acanthamoeba spp. In: Khan NA, editor. Emerging protozoan pathogens. New York, NY: Taylor and Francis; 2008. pp. 3-69.
3. Schuster FL, Visvesvara GS. Balamuthia mandrillaris. In: Khan NA, editor. Emerging protozoan pathogens. New York, NY: Taylor and Francis; 2008 pp. 71-118.
4. Marciano-Cabral F, Cabral G. Naegleria fowleri. In: Khan NA, editor. Emerging protozoan pathogens. New York, NY: Taylor and Francis; 2008. pp. 119-152.
5. Schuster FL, Visvesvara GS. Free-living amoebae as opportunistic and nonopportunistic pathogens of humans and animals. Int J Parasitol 2004; 34:1001-1027.
6. Niyyati M, Lorenzo-Morales J, Rezaeian M, et al. Isolation of Balamuthia mandrillaris from urban dust, free of known infectious involvement. Parasitol Res 2009; 106:279-281.
7. Verani JR, Lorick LA, Yoder JS, et al. National outbreak of Acanthamoeba keratitis associated with use of a contact lens solution, United States. Emerg Infect Dis 2009; 15:1236-1242.
8. Panjwani N. Pathogenesis of Acanthamoeba keratitis. Ocul Surf 2010; 8:70-79.
9. Dart JKG, Saw VPJ, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol 2009; 148:487-499.
10. Qvarnstrom Y, Da Silva AJ, Schuster FL, et al. Molecular confirmation of Sappinia pedata as causative agent of amebic encephalitis. J Infect Dis 2009; 199:1139-1142.
11. Sriram R, Shoff M, Booton G, et al. Survival of Acanthamoeba cysts after dessiccation for more than 20 years. J Clin Microbiol 2008; 46:4045-4048.
12. Dudley R, Jarroll EL, Khan NA. Carbohydrate analysis of Acanthamoeba castellanii. Exp Parasitol 2010; 122:338-343.
13. Corsaro D, Venditti D. Phylogenetic evidence for a new genotype of Acanthamoeba (Amoebozoa, Acanthamoebida). Parasitol Res 2010; 107:233-238.
14. Marciano-Cabral F, Cabral G. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 2003; 16:273-307.
15. Martinez MS, Gonzalez-Mediero G, Santiago P, et al. Granulomatous amebic encephalitis in a patient with AIDS. Isolation of Acanthamoeba sp. group II from brain tissue and successful treatment with sulfadiazine and fluconazole. J Clin Microbiol 2000; 38:3892-3895.
16. Saxena A, Mittal S, Burman P, Garg P. Acanthamoeba meningitis with successful outcome. Indian J Pediatr 2009; 76:1063-1064.
17. Petry F, Torzewski M, Bohl J, et al. Early diagnosis of Acanthamoeba infection during routine cytological examination of cerebrospinal fluid. J Clin Microbiol 2006; 44:1903-1904.
18. Walia R, Montoya JG, Visvesvara GS, et al. A case of successful treatment of Acanthamoeba infection in a lung transplant recipient. Transplant Infect Dis 2007; 9:51-54.
19. Fung KT-T, Dhillon AP, McLaughlin J, et al. Cure of Acanthamoeba cerebral abscess in a liver transplant patient. Liver Transpl 2008; 14:308-312.
20. Lackner P, et al. Acute granulomatous Acanthamoeba encephalitis in an immunocompetent patient. Neurocrit Care 2010; 12:91-94.
21. Aichelburg AC, Walochnik J, Assadian O, et al. Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine. Emerg Infect Dis 2008; 14:1743-1746.
22. Slater CA, Sickel J, Visvesvara GS, et al. Brief report: successful treatment of disseminated Acanthamoeba infection in an immunocompromised patient. N Engl J Med 1994; 331:85-87.
23. Roberts CW, Henriquez FL. Drug target identification, validation, characterization and exploitation for treatment of Acanthamoeba (species) infection. Exp Parasitol 2010; 126:91-96.
24. Walochnik J, Duchene M, Seifert K, et al. Cytotoxic activities of alkylpho-sphocholines against clinical isolates of Acanthamoeba spp. Antimicrob Agents Chemother 2002; 46:695-701.
25. Schuster FL, Guglielmo J, Visvesvara GS. In vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandril-laris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol 2006; 53:121-126.
26. Seal DV. Acanthamoeba keratitis update: incidence, molecular epidemiology and new drugs for treatment. Eye 2003; 17:893-905.
27. Walochnik J, Obwaller A, Gruber F, et al. Anti-Acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent. J Antimicrob Chemother 2009; 64:539-545.
28. McBride J, Mullen AB, Carter C, Roberts CW. Differential cytotoxicity of phospholipid analogues to pathogenic Acanthamoeba species and mammalian cells. J Antimicrob Chemother 2007; 60:521-525.
29. Rassu G, Gavini E, Mattana A, Giunchedi P. Improvement of antiamoebic activity of rokitamycin loaded in chitosan microspheres. Open Drug Deliv J 2008; 2:38-43.
30. Rassu G, Gavini E, Jonassen H, et al. New chitosan derivatives for the preparation of rokitamycin loaded microspheres designed for ocular or nasal administration. J Pharm Sci 2009; 98:4852-4865.
31. Bang S, Edell E, Eghrari AO, Gottsch JD. Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis. Am J Ophthalmol 2010; 149:66-69.
32. Bakardjiev A, Azimi PH, Ashouri N, et al. Amebic encephalitis caused by Balamuthia mandrillaris: report of four cases. Pediatr Infect Dis 2003; 22:447-452.
33. Galarza M, Cuccia V, Sosa FP, Monges JA. Pediatric granulomatous cerebral amebiasis: a delayed diagnosis. Pediatr Neurol 2002; 26:153-156.
34. Deetz TR, Sawyer TH, Billman G, et al. Successful treatment of Balamuthia amoebic encephalitis. Clin Infect Dis 2003; 37:1304-1312.
35. Jung S, Schelper RL, Visvesvara GS, Chang HT. Balamuthia mandrillaris meningoencephalitis in an immunocompetent patient. Arch Pathol Lab Med 2004; 128:466-468.
36. Schuster FL, Yagi S, Gavali S, et al. Under the radar: Balamuthia amebic encephalitis. Clin Infect Dis 2009; 48:879-887.
37. Cary LC, Maul E, Potter C, et al. Balamuthia mandrillaris meningoencephalitis; survival of a pediatric patient. Pediatrics 2010; 125:e699-e703.
38. Bravo FG, Cabrera J, Gottuzo E, Visvesvara GS. Cutaneous manifestations of infection by free-living amebas. In: Tropical dermatology, Tyring SK, Lupin O, Henggae UR, editors. Philadelphia: Elsevier; 2006. pp. 49-55.
39. Yoder JS, Eddy BA, Visvesvara GS, et al. The epidemiology of primary amoebic meningoencephalitis, 1962-2008. Epidemiol Infect 2010; 138: 968-975.
40. Seidel JS, Harmatz P, Visvesvara GS, et al. Successful treatment of primary amebic meningoencephalitis. N Engl J Med 1982; 306:346-348.
41. Kim J-H, Jung S-Y, Lee Y-J, et al. Effect of therapeutic chemical agents in vitro and on experimental meningencephalitis due to Naegleria fowleri. Antimicrob Agents Chemother 2008; 52:4010-4016.